BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12068842)

  • 1. Tibolone: new preparation. Menopausal symptoms: oestrogen-progestogen combinations are still the reference treatment.
    Prescrire Int; 2002 Jun; 11(59):79-82. PubMed ID: 12068842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P; Speroff L;
    Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.
    Liu JH
    Am J Med; 2005 Dec; 118 Suppl 12B():88-92. PubMed ID: 16414332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
    Jamin C; Bourg F; Legeai J; Senoussi S
    Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tibolone and its effects on bone: a review.
    Berning B; Bennink HJ; Fauser BC
    Climacteric; 2001 Jun; 4(2):120-36. PubMed ID: 11428176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-selectivity: the mechanism of action of tibolone.
    Kloosterboer HJ
    Maturitas; 2004 Aug; 48 Suppl 1():S30-40. PubMed ID: 15337246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tibolone on the breast of postmenopausal women.
    Wang PH; Cheng MH; Chao HT; Chao KC
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):121-6. PubMed ID: 17638619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options and menopause regimens.
    Farrell E
    Aust Fam Physician; 1992 Mar; 21(3):240-6. PubMed ID: 1605762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
    Hudita D; Posea C; Ceausu I; Rusu M
    Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoma of the endometrium in patients treated with tibolone.
    Yazigi R; Sahid S; Contreras L; Rodriguez T
    Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tibolone: a unique version of hormone replacement therapy.
    Swegle JM; Kelly MW
    Ann Pharmacother; 2004 May; 38(5):874-81. PubMed ID: 15026563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments.
    Kloosterboer HJ; Ederveen AG
    J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):157-65. PubMed ID: 12650712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women.
    Inan I; Kelekci S; Yilmaz B
    Gynecol Endocrinol; 2005 Feb; 20(2):64-7. PubMed ID: 15823823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone and breast cancer.
    Prescrire Int; 2010 Dec; 19(111):281. PubMed ID: 21355381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal estradiol: new formulation. Intranasal oestrogen delivery system: just a gimmick.
    Prescrire Int; 2002 Dec; 11(62):163-5. PubMed ID: 12469692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
    Diaby V; Perreault S; Lachaine J
    Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.